Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Common Equity: 2013-2025

Historic Common Equity for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $65.2 million.

  • Fortress Biotech's Common Equity rose 611.74% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year increase of 611.74%. This contributed to the annual value of $22.7 million for FY2024, which is 0.86% up from last year.
  • Latest data reveals that Fortress Biotech reported Common Equity of $65.2 million as of Q3 2025, which was up 48.40% from $43.9 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Common Equity registered a high of $248.3 million during Q2 2021, and its lowest value of -$15.9 million during Q2 2023.
  • Moreover, its 3-year median value for Common Equity was $19.8 million (2023), whereas its average is $13.3 million.
  • In the last 5 years, Fortress Biotech's Common Equity crashed by 119.88% in 2024 and then skyrocketed by 925.15% in 2025.
  • Quarterly analysis of 5 years shows Fortress Biotech's Common Equity stood at $225.9 million in 2021, then tumbled by 77.85% to $50.0 million in 2022, then plummeted by 54.93% to $22.5 million in 2023, then increased by 0.86% to $22.7 million in 2024, then soared by 611.74% to $65.2 million in 2025.
  • Its Common Equity was $65.2 million in Q3 2025, compared to $43.9 million in Q2 2025 and $32.5 million in Q1 2025.